Pharmafile Logo

News and Press Releases

Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours

Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...

Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024

Eisbach Bio
info@eisbach.bio
Am Klopferspitz 19, 82152 Planegg, Germany

ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team

6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...

Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024

The Institute of Cancer Research
123 Old Brompton Road London SW7 3RP

Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early

7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...

Category: Biotechnology
Posted: February 7, 2024

Informed Genomics
info@informedgenomics.com
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF

First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial

Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...

Category: Drug Discovery
Posted: February 7, 2024

Peptomyc
lsoucek@peptomyc.com
C/ Natzaret, 115-117 Barcelona, Spain, 08035

Landmark Phase 3 MARIPOSA Study Shows RYBREVANT▼(amivantamab) Plus Lazertinib Resulted in 30% Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC

Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from...

Category: Clinical Trials
Posted: October 24, 2023

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy

Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...

Category: Clinical Trials
Posted: October 23, 2023

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD  

· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma  · First Significant Improvement in Overall Survival in Two Decades...

Category: Pharmaceutical
Posted: October 23, 2023

Takeda Pharmaceutical Company
61 Aldwych, London, WC2B 4AE, UK

MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland

Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...

Category: Pharmaceutical
Posted: October 9, 2023

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Range of Highly Selective Anti-Idiotypic Antibodies Now Includes Six Antibodies Specific to Dupilumab and its Biosimilars for Bioanalysis and Drug Monitoring 5 October 2023 -- California, US -- Bio-Rad Laboratories,...

Category: Drug Discovery
Posted: October 5, 2023

Bio-Rad
UK_contact@bio-rad.com
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET

Bio-Rad Launches PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers 

Superior thermal performance and enhanced usability for PCR applications, such as sequencing, cloning and genotyping.  28 September 2023 -- California, US -- Bio-Rad Laboratories, a global leader in life science...

Category: Drug Discovery
Posted: September 28, 2023

Bio-Rad
UK_contact@bio-rad.com
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET